Výsledky vyhledávání - "Britte Kranenburg"

Economic burden of relapsed or refractory multiple myeloma: Results from an international trial

Autor: Abhishek Chitnis, Samuel Huse, Michael Stokes, Annette Lam, Don Robinson, Robert Z. Orlowski, Britte Kranenburg, Jianming He

Publikováno v: European Journal of Haematology. 99:119-132

Objective The direct cost of relapsed or refractory multiple myeloma (RRMM) is documented; indirect costs are being explored. Healthcare payers seek cost-offsets from therapies that improve clinical outcomes but challenge budgets; employers seek lowe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1e2729f1a45439439d084f342708bc4
https://doi.org/10.1111/ejh.12876

Zobrazit plný text záznamu

Plný text ve formátu HTML

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

Autor: Pierre W. Wijermans, Hong Xie, Peter M. Voorhees, Richard C. Frank, Robert Z. Orlowski, Brett Hall, Britte Kranenburg, Helgi van de Velde, Amrita Krishnan, Xiang Qin, Sonja Zweegman, Robert F. Manges, Sundar Jagannath, George Somlo, Tineke Casneuf, Suzanne Lentzsch, Sheeba K. Thomas, Pieter Sonneveld

Publikováno v: British Journal of Haematology, 161(3), 357-366. Wiley-Blackwell Publishing Ltd
British Journal of Haematology, 161(3), 357-366. Wiley-Blackwell
Voorhees, P M, Manges, R F, Sonneveld, P, Jagannath, S, Somlo, G, Krishnan, A, Lentzsch, S, Frank, R C, Zweegman, S, Wijermans, P W, Orlowski, R Z, Kranenburg, B, Hall, B, Casneuf, T, Qin, X, te Velde, H, Xie, H & Thomas, S K 2013, ' A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma ', British Journal of Haematology, vol. 161, no. 3, pp. 357-366 . https://doi.org/10.1111/bjh.12266

Interleukin-6 (IL6) plays a central role in multiple myeloma pathogenesis and confers resistance to corticosteroid-induced apoptosis. We therefore evaluated the efficacy and safety of siltuximab, an anti-IL6 monoclonal antibody, alone and in combinat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f4d4f74a2ddb95ff667d1cdffe50470
https://pure.eur.nl/en/publications/0520724d-84ac-4d5c-8ab7-27c36ead6b9c

Zobrazit plný text záznamu

A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome

Autor: Guillermo Garcia-Manero, David Valcárcel, Rami S. Komrokji, Martin R. Schipperus, Manjula Reddy, David P. Steensma, Britte Kranenburg, D. A. Breems, Raquel de Paz, Gary J. Gartenberg

Publikováno v: American journal of hematology. 89(9)

Interleukin-6 (IL-6) may play an important role in the pathophysiology of anemia of inflammation associated with myelodysplastic syndrome (MDS). This double-blind, placebo-controlled, phase 2 study assessed the efficacy and safety of siltuximab, a ch

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab3c4637d51a2df683a6b2e309a47277
https://pubmed.ncbi.nlm.nih.gov/24888488

Zobrazit plný text záznamu

Ibrutinib for the treatment of Mantle Cell Lymphoma (MCL): evaluating the correlation between patient-reported outcomes and durability of response in a Phase 2 study

Autor: Simon Rule, Sen Hong Zhuang, Netanel A. Horowitz, Rod Ramchandren, Mark Wildgust, S. Le Gouill, Michael Wang, Julia Alexeeva, Peter Martin, Ranjana H. Advani, Andre Goy, Zhong Yuan, Irit Avivi, William Deraedt, Aleksandra Rizo, Rakesh Popat, Britte Kranenburg

Publikováno v: Value in Health. 18:A300-A301

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9ef4cee557bf6f8e5fe5e3e5635293f
https://doi.org/10.1016/j.jval.2015.03.1750

Zobrazit plný text záznamu

Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Autor: Georg Lenz, Zhilong Yuan, Michael Wang, Simon Rule, Sriram Balasubramanian, Irit Avivi, Cuc Davis, Emily Stepanchick, Britte Kranenburg, William Deraedt, Sen Hong Zhuang, Regina Aquino, Aleksandra Rizo, Martin Dreyling, Michael Schaffer

Publikováno v: Blood. 124:78-78

Introduction: Ibrutinib, a first-in-class, once-daily, oral covalent inhibitor of Bruton’s tyrosine kinase is highly effective in relapsed or refractory mantle cell lymphoma (MCL) patients with an ORR of 68% (Wang M, et al. N Engl J Med. 2013;369:5

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4f693fb6e2ce42ce07677dab44cbd2a8
https://doi.org/10.1182/blood.v124.21.78.78

Zobrazit plný text záznamu

Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy

Autor: Zhilong Yuan, Britte Kranenburg, Ranjana H. Advani, Steven Le Gouill, Simon Rule, Andre Goy, Irit Avivi, Netanel A. Horowitz, Sen Hong Zhuang, William Deraedt, Julia Alexeeva, Peter Martin, Aleksandra Rizo, Rakesh Popat, Rod Ramchandren, Michael Wang

Publikováno v: Blood. 124:4471-4471

Introduction: Despite recent advances, mantle cell lymphoma (MCL) remains difficult to treat with frequent chemoresistance in the relapsed or refractory setting. Ibrutinib, a first-in-class, once-daily, oral covalent inhibitor of Bruton’s tyrosine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d109dd5f0ae40510c515d302c3818810
https://doi.org/10.1182/blood.v124.21.4471.4471

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání